
|Articles|April 26, 2023
AACU supports the PPI survey to update the MEI
Author(s)AACU
Advertisement
The American Medical Association is undertaking a 2023-2024 physician practice expense data collection effort with an independent research partner, Mathematica. The AACU is in favor of this effort in order provide an accurate update of the Medicare Economic Index and believes this survey is essential to the collection of practice cost information for use in our advocacy to support physicians. We have signed on to a letter that will be provided to each medical practice as part of the Mathematica invitation to participate in the survey effort.
The data will be shared with the Centers for Medicare & Medicaid Services in late 2024 to update the Medicare Economic Index and the Resource-Based Relative Value Scale.
Advertisement
Related to this article

Kim Chi, MD, FRCPC, discusses the rationale and design of the phase 3 KLK2-comPAS trial evaluating pasritamig alone and in combination with JNJ-9401 in patients with mCRPC.

Longer-term findings from the phase 2 ARACOG study suggest differences in objectively measured cognitive function between ARPIs.

Engy Habashy, MD, discusses key takeaways from the 2025 AUA GSM guideline, including the role of androgens and hormonal therapies in managing genitourinary syndrome of menopause.

Chad R. Ritch, MD, MBA, FACS, discusses how PSMA-PET informs staging, treatment planning, recurrence workup, and the interpretation of equivocal findings.

Michael S. Cookson, MD, MMHC, FACS, discusses how Anktiva’s expanded FDA approval may broaden bladder-preserving treatment options for BCG-unresponsive papillary-only NMIBC.

Jeffrey M. Spier, MD, discusses how fatigue may impact patient quality-of-life and when dose reduction may be an appropriate treatment strategy.

This approval expands the perioperative use of pembrolizumab plus enfortumab vedotin to all patients with MIBC, regardless of cisplatin eligibility.
Advertisement
Advertisement
Trending on Urology Times
1
How PSMA-PET shapes staging and recurrence workup in prostate cancer
2
ESMO 2026: Key presentations across genitourinary oncology
3
Engy Habashy, MD, on the role of androgens in GSM management
4
European Commission approves perioperative pembrolizumab plus enfortumab vedotin for MIBC
5

